PURPOSE: The randomised, controlled OSHO#39 study showed promising results using first-line mitoxantrone, chlorambucil and prednisolone (MCP) chemotherapy plus rituximab in patients with advanced symptomatic follicular lymphoma (FL) in need of therapy. The aim of this long-term follow-up was to investigate whether clinical benefits are maintained after up to 9 years of observation. METHODS: Following the 4-year follow-up of OSHO#39, 77 FL patients who received rituximab plus MCP (R-MCP) and 52 patients who receivedMCP (129 patients alive and not previously censored in total) were followed for 5 additional years in this prospective, non-interventional, observational study. For the efficacy analysis, data were jointly analysed with OSHO#39 data (FL intention-to-treat population: 105 patients R-MCP, 96 MCP). Patients not included in the 5-year follow-up were censored. RESULTS: For surviving patients, median follow-up was 102 months (R-MCP) and 87 months (MCP). Although median overall survival (OS) was not yet reached, OS was longer for patients with R-MCP compared with MCP (p = 0.0057), with 8-year-survival rates of 76.1 versus 55.9%. Further time-to-event data were substantially longer for the R-MCP group than for MCP alone: median progression-free survival (PFS) was 93.4 versus 34.9 months, and median event-free survival (EFS) 89.6 versus 26.5 months. Unplanned subanalyses of patients with and without interferon maintenance showed improved PFS and EFS without an impact on OS. CONCLUSIONS: The addition of rituximab to first-line MCP chemotherapy improves clinical outcomes in advanced FL patients and translates into long-term OS benefits. R-MCP remains a promising standard option for this patient group.
RCT Entities:
PURPOSE: The randomised, controlled OSHO#39 study showed promising results using first-line mitoxantrone, chlorambucil and prednisolone (MCP) chemotherapy plus rituximab in patients with advanced symptomatic follicular lymphoma (FL) in need of therapy. The aim of this long-term follow-up was to investigate whether clinical benefits are maintained after up to 9 years of observation. METHODS: Following the 4-year follow-up of OSHO#39, 77 FL patients who received rituximab plus MCP (R-MCP) and 52 patients who received MCP (129 patients alive and not previously censored in total) were followed for 5 additional years in this prospective, non-interventional, observational study. For the efficacy analysis, data were jointly analysed with OSHO#39 data (FL intention-to-treat population: 105 patientsR-MCP, 96 MCP). Patients not included in the 5-year follow-up were censored. RESULTS: For surviving patients, median follow-up was 102 months (R-MCP) and 87 months (MCP). Although median overall survival (OS) was not yet reached, OS was longer for patients with R-MCP compared with MCP (p = 0.0057), with 8-year-survival rates of 76.1 versus 55.9%. Further time-to-event data were substantially longer for the R-MCP group than for MCP alone: median progression-free survival (PFS) was 93.4 versus 34.9 months, and median event-free survival (EFS) 89.6 versus 26.5 months. Unplanned subanalyses of patients with and without interferon maintenance showed improved PFS and EFS without an impact on OS. CONCLUSIONS: The addition of rituximab to first-line MCP chemotherapy improves clinical outcomes in advanced FL patients and translates into long-term OS benefits. R-MCP remains a promising standard option for this patient group.
Authors: Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet Journal: Blood Date: 2005-09-08 Impact factor: 22.113
Authors: Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt Journal: Blood Date: 2005-08-25 Impact factor: 22.113
Authors: Qi Liu; Luis Fayad; Fernando Cabanillas; Fredrick B Hagemeister; Gregory D Ayers; Mark Hess; Jorge Romaguera; M Alma Rodriguez; Apostolia M Tsimberidou; Srdan Verstovsek; Anas Younes; Barbara Pro; Ming-Sheng Lee; Ana Ayala; Peter McLaughlin Journal: J Clin Oncol Date: 2006-04-01 Impact factor: 44.544
Authors: A Z S Rohatiner; W M Gregory; B Peterson; E Borden; P Solal-Celigny; A Hagenbeek; R I Fisher; M Unterhalt; R Arranz; T Chisesi; A Aviles; T A Lister Journal: J Clin Oncol Date: 2005-01-31 Impact factor: 44.544
Authors: Robert Marcus; Kevin Imrie; Philippe Solal-Celigny; John V Catalano; Anna Dmoszynska; João C Raposo; Fritz C Offner; José Gomez-Codina; Andrew Belch; David Cunningham; Elisabeth Wassner-Fritsch; George Stein Journal: J Clin Oncol Date: 2008-07-28 Impact factor: 44.544
Authors: Michael Herold; Antje Haas; Stefanie Srock; Sabine Neser; Kathrin Haifa Al-Ali; Andreas Neubauer; Gottfried Dölken; Ralph Naumann; Wolfgang Knauf; Mathias Freund; Robert Rohrberg; Klaus Höffken; Astrid Franke; Thomas Ittel; Erika Kettner; Ursula Haak; Ulrich Mey; Christian Klinkenstein; Michael Assmann; Ullrich von Grünhagen Journal: J Clin Oncol Date: 2007-04-09 Impact factor: 44.544
Authors: Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Simone Thomas; Tobias Pukrop; Christina Hackl; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle Journal: Front Pharmacol Date: 2018-11-28 Impact factor: 5.810